IN8BIO, INC. Files 2023 Annual Report on Form 10-K

Ticker: INAB · Form: 10-K · Filed: Mar 14, 2024 · CIK: 1740279

In8bio, Inc. 10-K Filing Summary
FieldDetail
CompanyIn8bio, Inc. (INAB)
Form Type10-K
Filed DateMar 14, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.0001, $1.54, $14.8 million, $17.7 million
Sentimentneutral

Sentiment: neutral

Topics: 10-K, IN8BIO, Biotechnology, Annual Report, Financials

TL;DR

<b>IN8BIO, INC. has filed its 2023 10-K report, providing a comprehensive overview of its operations and financial standing.</b>

AI Summary

IN8BIO, INC. (INAB) filed a Annual Report (10-K) with the SEC on March 14, 2024. IN8BIO, INC. filed its 2023 10-K report on March 14, 2024, detailing its fiscal year ending December 31, 2023. The company's principal executive offices are located at the Empire State Building, 350 5th Avenue, Suite 5330, New York, NY 10118. IN8BIO, INC. was formerly known as Incysus Therapeutics, Inc., with a name change effective May 10, 2018. The filing references various equity and warrant agreements, including the 'TwoThousandAndTwentyEmployeeStockPurchasePlan' and 'SeriesAWarrants'. The company's Standard Industrial Classification is 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' [2836].

Why It Matters

For investors and stakeholders tracking IN8BIO, INC., this filing contains several important signals. This 10-K filing provides investors and stakeholders with the latest official financial and operational data for IN8BIO, INC., crucial for evaluating the company's performance and future prospects. The detailed information on various agreements, stock plans, and historical company data helps in understanding the company's corporate structure, past activities, and potential future capitalizations.

Risk Assessment

Risk Level: medium — IN8BIO, INC. shows moderate risk based on this filing. The filing is a standard 10-K, which typically contains forward-looking statements and risk factors inherent to the biotechnology industry, requiring careful review by investors.

Analyst Insight

Review the detailed financial statements and risk factors within the 10-K to assess IN8BIO, INC.'s current financial health and potential growth opportunities in the biotechnology sector.

Key Numbers

  • 2023-12-31 — Fiscal Year End (The end date of the reporting period for the 10-K.)
  • 2024-03-14 — Filing Date (The date the 10-K was filed with the SEC.)
  • 001-39692 — SEC File Number (The SEC file number associated with the company.)
  • 0000950170-24-031486 — Accession Number (The accession number for this specific filing.)
  • 116 — Public Document Count (The number of documents included in the filing.)
  • 2018-05-10 — Date of Name Change (The effective date of the name change from Incysus Therapeutics, Inc. to IN8BIO, INC.)

Key Players & Entities

  • IN8BIO, INC. (company) — Filer name and subject of the 10-K filing.
  • Incysus Therapeutics, Inc. (company) — Former name of IN8BIO, INC.
  • 2023-12-31 (date) — Conformed period of report for the 10-K filing.
  • 2024-03-14 (date) — Filing date of the 10-K report.
  • Empire State Building (location) — Street address for the company's business and mailing address.
  • New York (location) — City for the company's business and mailing address.
  • DE (location) — State of incorporation for IN8BIO, INC.
  • 2836 (industry_code) — Standard Industrial Classification code for Biological Products.

FAQ

When did IN8BIO, INC. file this 10-K?

IN8BIO, INC. filed this Annual Report (10-K) with the SEC on March 14, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by IN8BIO, INC. (INAB).

Where can I read the original 10-K filing from IN8BIO, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by IN8BIO, INC..

What are the key takeaways from IN8BIO, INC.'s 10-K?

IN8BIO, INC. filed this 10-K on March 14, 2024. Key takeaways: IN8BIO, INC. filed its 2023 10-K report on March 14, 2024, detailing its fiscal year ending December 31, 2023.. The company's principal executive offices are located at the Empire State Building, 350 5th Avenue, Suite 5330, New York, NY 10118.. IN8BIO, INC. was formerly known as Incysus Therapeutics, Inc., with a name change effective May 10, 2018..

Is IN8BIO, INC. a risky investment based on this filing?

Based on this 10-K, IN8BIO, INC. presents a moderate-risk profile. The filing is a standard 10-K, which typically contains forward-looking statements and risk factors inherent to the biotechnology industry, requiring careful review by investors.

What should investors do after reading IN8BIO, INC.'s 10-K?

Review the detailed financial statements and risk factors within the 10-K to assess IN8BIO, INC.'s current financial health and potential growth opportunities in the biotechnology sector. The overall sentiment from this filing is neutral.

Key Dates

  • 2024-03-14: 10-K Filing — Official filing of the company's annual report for fiscal year 2023.

Filing Stats: 4,471 words · 18 min read · ~15 pages · Grade level 16.3 · Accepted 2024-03-14 16:11:35

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share INAB The Nasdaq
  • $1.54 — gistrant, based on the closing price of $1.54 per share of the Registrant's common st
  • $14.8 million — placement, we may receive an additional $14.8 million in aggregate proceeds if the holders of
  • $17.7 million — may also receive aggregate proceeds of $17.7 million from the exercise of our outstanding Se

Filing Documents

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 46 Item 1B. Unresolved Staff Comments 91 Item 1C. Cybersecurity 91 Item 2.

Properties

Properties 93 Item 3.

Legal Proceedings

Legal Proceedings 93 Item 4. Mine Safety Disclosures 93 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 94 Item 6. [Reserved] 94 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 95 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 105 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 105 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 127 Item 9A.

Controls and Procedures

Controls and Procedures 127 Item 9B. Other Information 128 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 128 PART III Item 10. Directors, Executive Officers and Corporate Governance 129 Item 11.

Executive Compensation

Executive Compensation 129 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 129 Item 13. Certain Relationships and Related Transactions, and Director Independence 129 Item 14. Principal Accountant Fees and Services 129 PART IV Item 15. Exhibits and Financial Statement Schedules 130 Item 16. Form 10-K Summary 133

Signatures

Signatures In this report, unless otherwise stated or the context otherwise indicates, the terms "IN8bio, Inc.," "the company," "we," "us," "our" and similar references refer to IN8bio, Inc. "IN8BIO," "INEIGHTBIO," "Cancer Zero," the IN8BIO logo, DeltEx and other trademarks, trade names or service marks of IN8bio, Inc. appearing in this Annual Report are the property of IN8bio, Inc. All other trademarks, trade names and service marks appearing in this Annual Report are the property of their respective owners. Solely for convenience, the trademarks and trade names in this report may be referred to without the and symbols, but such references should not be construed as any indicator that their respective owners will not assert their rights thereto. The images found on pages 13, 17, 21 and 26 of this Annual Report were created with biorender.com and the image found on page 29 of this Annual Report was from BioPharma Dealmakers, March 2023. i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K, or this Annual Report, contains statements that may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve substantial risks and uncertainties. All statements contained in this Annual Report on Form 10-K other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words "believes," "expects," "intends," "estimates," "projects," "anticipates," "will," "plan," "may," "should," or similar language are intended to identify forward-looking statements. These forward-looking statements include statements concerning the following: our ability to mitigate the substantial doubt to continue

B usiness

Item 1. B usiness. Overview We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties. They are naturally occurring immune cells that can intrinsically differentiate between healthy and diseased tissue. These cells serve as a functional bridge between innate and adaptive immunity to contribute to direct tumor killing, as well as immune cell recruitment and activation to drive deeper and more comprehensive immune responses. The pivotal role of gamma-delta T cells in immune function and activation against diseases such as cancer underscores their therapeutic potential across a wide range of solid and hematologic malignancies. We develop ex vivo-expanded and activated gamma-delta T cell candidates based upon our deep expertise in gamma-delta T cell biology, proprietary genetic engineering, and cell-type specific manufacturing capabilities, which we refer to collectively as our DeltEx platform. Our platform employs allogeneic, autologous, induced pluripotent stem cell, or iPSC, and genetically modified cell therapy approaches that are designed to effectively identify and eradicate tumor cells. We are the most clinically advanced gamma-delta T cell focused cellular therapy company and are utilizing our suite of DeltEx platform technologies as we aspire to eliminate cancer cells to achieve our mission of what we refer to as Cancer Zero the safe elimination of all cancer cells in every patient battling the disease. We believe this lofty aspiration will one day be achievable and that it is our responsibility to directly contribute to related global health efforts by pursuing scientific research that will advance cancer treatment. We recently initiated enrollment in our Phase 2 multi-center clinical trial of our lead product candidate, INB-400, for the treatme

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.